Moreover, engineered exosomes delivering an antisense oligonucleotide targeting STAT6 can selectively silence STAT6 expression in tumor-associated macrophages (TAMs), which may help us to reprogram TAMs toward a pro-inflammatory M1 phenotype to heighten CD8+ T cells efficacy in the TME [113]. The gene discussed is CD8A; the disease is neoplasm.